FY2026 Earnings Forecast for Immunic Issued By William Blair

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Investment analysts at William Blair issued their FY2026 earnings estimates for Immunic in a research report issued on Monday, March 24th. William Blair analyst M. Minter expects that the company will earn ($0.98) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic's FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.96 EPS.

Several other equities research analysts also recently commented on the company. D. Boral Capital reiterated a "buy" rating and issued a $17.00 price objective on shares of Immunic in a report on Wednesday, February 26th. StockNews.com lowered shares of Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Immunic in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $12.67.

Remove Ads

Immunic Trading Down 7.1 %

IMUX traded down $0.09 during trading on Thursday, hitting $1.12. 614,226 shares of the company's stock traded hands, compared to its average volume of 604,248. Immunic has a 12-month low of $0.92 and a 12-month high of $2.11. The company's 50 day simple moving average is $1.08 and its two-hundred day simple moving average is $1.21. The stock has a market capitalization of $100.44 million, a price-to-earnings ratio of -0.91 and a beta of 1.89.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC bought a new position in Immunic in the 3rd quarter worth $50,000. Invesco Ltd. purchased a new stake in Immunic in the fourth quarter worth about $37,000. Jane Street Group LLC raised its stake in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after buying an additional 38,553 shares during the period. HB Wealth Management LLC purchased a new position in shares of Immunic during the 4th quarter valued at about $81,000. Finally, Barclays PLC bought a new position in shares of Immunic during the 4th quarter valued at approximately $84,000. Hedge funds and other institutional investors own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.